Search results for "Adverse effect"

showing 10 items of 1065 documents

Cardiovascular Responses to Muscle Stretching: A Systematic Review and Meta-analysis

2021

AbstractThe aim of this study will be to review the current body of literature to understand the effects of stretching on the responses of the cardiovascular system. A literature search was performed using the following databases: Scopus, NLM Pubmed and ScienceDirect. Studies regarding the effects of stretching on responses of the cardiovascular system were investigated. Outcomes regarded heart rate(HR), blood pressure, pulse wave velocity (PWV of which baPWV for brachial-ankle and cfPWV for carotid-femoral waveforms), heart rate variability and endothelial vascular function. Subsequently, the effects of each outcome were quantitatively synthetized using meta-analytic synthesis with random-…

Data Analysismedicine.medical_specialtyBlood PressurePhysical Therapy Sports Therapy and RehabilitationPulse Wave AnalysisCardiovascular SystemCardiovascular Physiological PhenomenastiffnessVascular StiffnessvascularMuscle Stretching ExercisesInternal medicineHeart ratemedicineheart rateHumansHeart rate variabilityAnkle Brachial IndexArterial PressureOrthopedics and Sports Medicineheart rate; stiffness; stretching; vascularAdverse effectheart rate stiffness stretching vascularPulse wave velocitybusiness.industrystretchingmedicine.diseaseFemoral ArteryCarotid ArteriesBlood pressureCarotid-Femoral Pulse Wave VelocityMeta-analysisArterial stiffnessCardiologyEndothelium VascularMuscle stretchingbusiness
researchProduct

The clinical safety of disabled patients: proposal for a methodology for analysis of health care risks and specific measures for improvement

2012

The clinical risks associated with health care have been a known factor since ancient times, and their prevention has constituted one of the foundations of health care. However, concern for the risks involved in health care treatments has risen very significantly in recent years, becoming a modern current of concern for clinical health care risks which is referred to by the name of “patient safety” in the scientific literature. Unfortunately, there are no studies on patient safety in dental practice or case studies of adverse events in this practice. In addition to the lack of studies on adverse events in regular dental practice, there are even fewer references to treatment for disabled pat…

Dental practiceSafety Managementmedicine.medical_specialtyDental Care for Disabledbusiness.industryReview-ArticleOdontologíaScientific literature:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludPatient safetyOtorhinolaryngologyNursingFamily medicineUNESCO::CIENCIAS MÉDICASHealth caremedicineHumansClinical safetyOdontostomatology for the Disabled or Special PatientsSurgeryPatient SafetyAdverse effectbusinessGeneral Dentistry
researchProduct

Analysis of 415 adverse events in dental practice in Spain from 2000 to 2010

2013

Introduction: The effort to increase patient safety has become one of the main focal points of all health care profes - sions, despite the fact that, in the field of dentistry, initiatives have come late and been less ambitious. The main objective of patient safety is to avoid preventable adverse events to the greatest extent possible and to limit the negative consequences of those which are unpreventable. Therefore, it is essential to ascertain what adverse events occur in each dental care activity in order to study them in-depth and propose measures for prevention. Objectives: To ascertain the characteristics of the adverse events which originate from dental care, to classify them in acco…

Dental practicemedicine.medical_specialtyPathologyTime FactorsAlternative medicineMEDLINEOdontologíaPatient safetyMalpracticeHealth caremedicineHumansIntensive care medicineAdverse effectDental CareGeneral DentistryMedical Errorsbusiness.industryResearch:CIENCIAS MÉDICAS [UNESCO]EndodonticsCiencias de la saludOtorhinolaryngologySpainUNESCO::CIENCIAS MÉDICASSurgeryPatient SafetyOral Surgerybusiness
researchProduct

Nutraceuticals in Lipid-Lowering Treatment

2014

Lipid-lowering drugs may cause adverse effects and, although lipid targets may be achieved, a substantial residual cardiovascular (CV) risk remains. Treatment with agents mimicking proteins present in the body, such as incretin-based therapies, provided promising results. However, in order to improve lipids and CV risk, lifestyle measures remain important. Some researchers focused on nutraceuticals that may beneficially affect metabolic parameters and minimize CV risk. Chitosan, a dietary fiber, can regulate lipids with benefit on anthropometric parameters. The beneficial properties of dietary supplements (such as green tea extract, prebiotics, plant sterols, and stanols) on plasma lipids,…

Dietary Fibermedicine.medical_treatmentGreen tea extractPharmacologyChitosanchemistry.chemical_compoundNutraceuticallipidRisk FactorsmedicineAnimalsHumansAdverse effectDyslipidemiasHypolipidemic AgentsChitosanTraditional medicinebusiness.industryMedicine (all)InsulinlipoproteinLipidsClinical trialTreatment OutcomeBlood pressurechemistryCardiovascular Diseasesdietary supplementDietary SupplementsnutraceuticalLipid loweringCardiology and Cardiovascular MedicinebusinessBiomarkersAngiology
researchProduct

The Association of Intraoperative driving pressure with postoperative pulmonary complications in open versus closed abdominal surgery patients – a po…

2021

Abstract Background It is uncertain whether the association of the intraoperative driving pressure (ΔP) with postoperative pulmonary complications (PPCs) depends on the surgical approach during abdominal surgery. Our primary objective was to determine and compare the association of time–weighted average ΔP (ΔPTW) with PPCs. We also tested the association of ΔPTW with intraoperative adverse events. Methods Posthoc retrospective propensity score–weighted cohort analysis of patients undergoing open or closed abdominal surgery in the ‘Local ASsessment of Ventilatory management during General Anaesthesia for Surgery’ (LAS VEGAS) study, that included patients in 146 hospitals across 29 countries.…

Driving pressure; Laparoscopic surgery; Laparoscopy; PEEP; Perioperative ventilation; Pneumoperitoneum; Protective ventilation; Respiratory mechanics;Lung DiseasesMaleLaparoscopic surgery[SDV]Life Sciences [q-bio]medicine.medical_treatmentLaparoscopic surgeryCohort StudiesPositive-Pressure RespirationPostoperative Complications0302 clinical medicinePneumoperitoneum030202 anesthesiologyPneumoperitoneumAbdomenClinical endpointPerioperative ventilationMiddle Aged3. Good healthDriving pressure Laparoscopic surgery Laparoscopy PEEP Perioperative ventilation Pneumoperitoneum Protective ventilation Respiratory mechanicsDriving pressureFemaleResearch ArticleCohort studyProtective ventilationAdultmedicine.medical_specialtyAnestesi och intensivvårdRespiratory mechanicsAnesthesia GeneralNOlcsh:RD78.3-87.303 medical and health sciencesmedicineHumansPropensity ScoreAdverse effectPEEPAgedRetrospective StudiesDriving pressure; Laparoscopic surgery; Laparoscopy; PEEP; Perioperative ventilation; Pneumoperitoneum; Protective ventilation; Respiratory mechanicsAnesthesiology and Intensive Carebusiness.industryKirurgi030208 emergency & critical care medicineOdds ratiomedicine.diseaseRespiration ArtificialSurgeryAnesthesiology and Pain Medicinelcsh:AnesthesiologyRelative riskSurgeryLaparoscopyDriving pressure ; Laparoscopic surgery ; Laparoscopy ; PEEP ; Perioperative ventilation ; Pneumoperitoneum ; Protective ventilation ; Respiratory mechanics.businessAbdominal surgery
researchProduct

Uso degli inibitori di pompa protonica in un Policlinico Universitario

2012

Summary Introduction Proton pump inhibitors (PPIs) are highly prescribed drugs in Italy and in particular in the Sicilian region but little is known about their use in the hospital setting. Materials and methods PPI utilization and related costs were reviewed retrospectively by examining the pharmaceutical records of drug dispensation to the various wards of the Policlinico Universitario P. Giaccone of Palermo in 2010. Differences in the prescribing rates and drug preferences among the different clinical wards were analyzed. Results A total of 20,420 patients were hospitalized at the Policlinico of Palermo in 2010. Overall, the consumption of PPIs was 120 DDD/100 bed-days for the year 2010 …

Drug Utilizationmedicine.medical_specialtybusiness.industryHospital settingObesity SurgeryGeneral MedicinePrimary careProton pump inhibitorEsomeprazolePrescribing appropriateneSettore MED/02 - Storia Della MedicinaHospitalDrug utilizationSettore BIO/14 - FarmacologiaMedicineMedical prescriptionbusinessIntensive care medicineAdverse effectPrescribed drugsmedicine.drugDDD
researchProduct

Safety study of sodium pentosan polysulfate for adult patients with mucopolysaccharidosis type II

2019

Current therapies for the mucopolysaccharidoses (MPS) do not effectively address skeletal and neurological manifestations. Pentosan polysulfate (PPS) is an alternative treatment strategy that has been shown to improve bone architecture, mobility, and neuroinflammation in MPS animals. The aims of this study were to a) primarily establish the safety of weekly PPS injections in attenuated MPS II, b) assess the efficacy of treatment on MPS pathology, and c) define appropriate clinical endpoints and biomarkers for future clinical trials. Subcutaneous injections were administered to three male Japanese patients for 12 weeks. Enzyme replacement therapy was continued in two of the patients while th…

Drug0301 basic medicinemedicine.medical_specialtymedia_common.quotation_subjectEndocrinology Diabetes and MetabolismClinical BiochemistryeducationUrologymucopolysaccharidosis IIBiochemistryArticlePPSrange of motion03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineClinical endpointglycosaminoglycanGeneticsMedicineMucopolysaccharidosis type IIAdverse effectMolecular Biologyhealth care economics and organizationsmedia_commonbiologyAdult patientsanti-inflammatory factorbusiness.industryEnzyme replacement therapyPentosan polysulfateClinical trial030104 developmental biologyAlanine transaminasebiology.proteinSodium Pentosan Polysulfatebusiness030217 neurology & neurosurgerymedicine.drugMolecular Genetics and Metabolism
researchProduct

The Influence of Single-Dose and Short-Term Administration of Quercetin on the Pharmacokinetics of Midazolam in Humans.

2015

Quercetin is a plant flavonol that is available from both daily diet and nutraceuticals. To investigate the effect of acute and short-term intake of high-dose quercetin on CYP3A-mediated metabolism, 10 healthy volunteers received 7.5 mg oral midazolam without, with a single dose of 1500 mg quercetin and after 1-week supplementation with 1500 mg quercetin daily. A substudy was performed in three subjects to explore the impact of repeated quercetin intake on intravenously administered midazolam. Coadministration with a single dose of quercetin did not significantly alter the pharmacokinetics of midazolam and its 1'-hydroxymetabolite, but following short-term quercetin intake, there was a tren…

DrugAdultMalemedia_common.quotation_subjectMidazolamPharmaceutical ScienceAdministration OralPharmacologychemistry.chemical_compoundPharmacokineticsmedicineCytochrome P-450 CYP3AHumansheterocyclic compoundsDrug InteractionsAdverse effectmedia_commonCross-Over StudiesbiologyCytochrome P450MetabolismBioavailabilitychemistryArea Under Curvebiology.proteinMidazolamAdministration IntravenousFemaleQuercetinQuercetinmedicine.drugJournal of pharmaceutical sciences
researchProduct

Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole

2003

Managing invasive fungal infections often presents a challenge for clinicians in the treatment of immunocompromised patients. Two very different systemic antifungal agents, voriconazole and caspofungin, have recently been introduced into the market place. Voriconazole is a new triazole antifungal, while caspofungin is the first echinocandin antifungal. Voriconazole acts by inhibiting the synthesis of ergosterol in the fungal cell membrane. Caspofungin inhibits beta-1,3-D-glucan synthesis in the cell wall, a target present in fungal cells, but absent from mammalian cells. Both agents are broad-spectrum, with efficacy against invasive Aspergillus and Candida infections. The safety and tolerab…

DrugAntifungal AgentsEchinocandinmedia_common.quotation_subjectPharmacologyPeptides CyclicEchinocandinsLipopeptideschemistry.chemical_compoundCaspofunginpolycyclic compoundsmedicineAspergillosisHumansDrug InteractionsAdverse effectmedia_commonVoriconazoleClinical Trials as Topicbusiness.industryCandidiasisGeneral MedicineTriazolesDrug interactionClinical trialPyrimidinesTreatment OutcomeTolerabilitychemistryVoriconazoleCaspofunginPeptidesbusinessmedicine.drugCurrent Medical Research and Opinion
researchProduct

Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin.

2009

Abstract Coadministration of the iron chelator dexrazoxane reduces by 80% the incidence of heart failure in cancer patients treated with anthracyclines. The clinical application of dexrazoxane is limited, however, because its ability to inhibit topoisomerase IIα (TOP2A) is feared to adversely affect anthracycline chemotherapy, which involves TOP2A-mediated generation of DNA double-strand breaks (DSB). Here, we investigated the apoptotic effects of dexrazoxane and the anthracycline doxorubicin, alone and in combination, in a tumor cell line with conditionally regulated expression of TOP2A. Each drug caused apoptosis that was only partly dependent on TOP2A. Unexpectedly, dexrazoxane was found…

DrugCancer ResearchAnthracyclinemedicine.medical_treatmentmedia_common.quotation_subjectAntineoplastic AgentsApoptosisPharmacologyHistonesAntigens NeoplasmCell Line TumormedicineHumansDoxorubicinAdverse effectPoly-ADP-Ribose Binding Proteinsmedia_commonCaspase 7ChemotherapyChemistryCaspase 3Gene Expression ProfilingCancermedicine.diseaseGlutathioneDNA-Binding ProteinsGene Expression Regulation NeoplasticDNA Topoisomerases Type IIOncologyApoptosisDoxorubicinCancer researchDexrazoxaneTumor Suppressor Protein p53Razoxanemedicine.drugMolecular cancer therapeutics
researchProduct